Status:
COMPLETED
EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer
Lead Sponsor:
University of Tehran
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
Pancreatic cancer is the 11th most common type of cancer but it is the fourth leading cause of cancer death. The only effective treatment for pancreatic cancer includes surgery. However, only 20% of t...
Detailed Description
In this study, gemcitabine will be injected directly into the tumor by means of endoscopic ultrasound (EUS) in the eligible patients.
Eligibility Criteria
Inclusion
- Patients with histologically verified pancreatic adenocarcinoma who have locally advanced unresectable tumor
Exclusion
- Early stage resectable pancreatic cancer with the intact surrounding major vessels on imaging
- Pancreatic cancer with distant metastasis
- Unwilling to sign informed consent
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01834170
Start Date
April 1 2013
End Date
December 1 2014
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Digestive Disease Research Center, Shariati ospital
Tehran, Iran